Effects of neuropeptide derivate FPF 1070 (cerebrolysin) administration on experimental acute spinal cord injury

Pan Arab Journal of Neurosurgery

Volumn 11, Issue 1, 2007, Pages 50-61

  Abdelaziz, Osama S ^a   Elbanna, Yasser M ^a   Elnaggar, Alaa M ^a   Mourad, Chada M ^a   Mohammad, Sahar A ^a  

^a ALEXANDRIA UNIVERSITY   (Egypt)

Author keywords

Cerebrolysin; Neuroprotection and spinal cord injury

Indexed keywords

CEREBROLYSIN; EOSIN; HEMATOXYLIN; TOLONIUM CHLORIDE;

ACUTE DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; EXPERIMENTAL DOG; HISTOPATHOLOGY; INJURY SEVERITY; LAMINECTOMY; MALE; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; SPINAL CORD INJURY; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 34248219474     PISSN: 13196995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (77)

1. Akai F, Hiruma S, Sato T, et al: Neurotrophic factor-like effect of FPF1070 on septal cholinergic neurons after transection of fimbria-fornix in the rat brain. Histol Histopathol 1992, 7: 213-221
2. Akpek EA, Bulutcu E, Alanay A, et al: A study of adenosine treatment in experimental acute spinal cord injury. Spine 1999, 24(2): 128-132
3. Albrecht E, Hingel S, Crailsheim K, Windisch M: The effect of cerebrolysin on the vitality and sprouting of neurons from cerebral hemispheres and from the brain stem of chicken embryos in vitro. Neurobiol Aging 1992, 13(1): 127-138
4. Alvarez XA, Lombardi VR, Novoa LF, Garcia M: Cerebrolysin reduces microglial activation in vivo and in vitro: A potential mechanism of neuroprotection. J Neural Transm 2000, 59: 281-292
5. Anderson DK: Chemical and cellular mediators in spinal cord injury. J Neurotrauma 1992, 9: 143-146
6. Anderson DK, Hall ED: Pathophysiology of spinal cord trauma. Ann Emerg Med 1993, 22: 987-992
7. Bae CY, Ton Cho C, Kyunghee C, Hoon B: A double blind placebo controlled multicentre study of cerebrolysin for Alzheimer's disease. J Am Geriatr Soc 2000, 48: 1566-1571
8. Balentine JD, Paris DU: Pathology of experimental spinal cord trauma. Lab Invest 1978, 39: 254-266
9. Balenty E: Ergebnisse der Anwendung von Cerebrolysin an Patienten mit Morbus Parkinson. Neuropsych 1987, 1: 94-96
10. nd Ed, Edinburgh, London, Madrid; Churchill Livingstone, 1994, p345
11. Bartus RT, Dean RL, Cavanaugh K, et al: Time related neuronal changes following middle cerebral artery occlusion: Implications for therapeutic intervention and the role of calpain. J Cereb Blood Flow Metab 1995, 15: 969-979
12. Baskys A, Wojtowicz JM: Actions of organ derived preparations on synaptic transmission in the hippocampus. Neurobiol Aging 1992, 13(1): 128
13. Biesenbach G, Eichbauer-Sturm G, Grafinger P, Zazgomik J: Effect of cerebrolysin in the treatment of painful diabetic neuropathy in Type 2 diabetic patients. Euro Rehab 1997, 3-4: 97-103
14. Blumbergs P: Changing concepts of diffuse axonal injury. J Clin Neurosci 1998, 5: 123-124
15. Boado RJ: Neuropeptides increase the expression of a blood-brain barrier GLUT1 glucose transporter gene. Neurosci Lett 1996, 220: 53-56
16. Boado RJ, Dafang WU, Manfred W: In vivo up regulation of the blood-brain barrier GLUT1 glucose transporter by brain derived peptides. Neurosci Res 1999, 34: 217-224
17. Bracken MB, Collins WF, Freeman DF, et al: Efficacy of methylprednisolone in acute spinal cord injury. JAMA 1984, 251: 45-52
18. Bracken MB, Shepard MJ, Hellenbrand KG, et al: Methylprednisolone and neurological function 1 year after spinal cord injury: Results of the National Acute Spinal Cord Injury Study. J Neurosurg 1985, 63: 704-713
19. Bracken MB, Shepard MJ, Collins WF, et al: A randomised, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal cord injury: Results of the Second National Acute Spinal Cord Injury Study (NASCIS). N Engl J Med 1990, 322: 1405-1411
20. Bracken MB, Shepard MJ, Collins WF, et al: Methylprednisolone or naloxone treatment after acute spinal cord injury: One-year follow-up data: Results of the Second National Acute Spinal Cord Injury Study (NASCIS). J Neurosurg 1992, 76: 23-31
21. Bracken MB, Shepard MJ, Holford TR, et al: Administration of methylprednisolone for 24 or 48 hours or tirilasad mesylate for 48 hours in the treatment of acute spinal cord injury: Results of the Third National Acute Spinal Cord Injury Study (NASCIS). JAMA 1997, 277: 1597-1604
22. Bracken MB, Shepard MJ, Holford TR, et al: Methylprednisolone or tirilasad mesylate administration after acute spinal cord injury. One year follow-up: Results of the Third National Acute Spinal Cord Injury Study (NASCIS). J Neurosurg 1998, 89: 699-706
23. Cornish R, Health B, Blumbergs PC, et al: Topography and severity of axonal injury in human spinal cord trauma using amyloid precursor protein as a marker of axonal injury. Spine 2000, 25(10): 1227-1233
24. th Ed, Philadelphia, London, Toronto; WB Saunders Company, 1994, 1(34): pp1295-1356
25. Dela Torre JC: Spinal cord injury: Review of basic and applied research. Spine 1981, 6: 315-335
26. Dimar JR, Shield CB, Zhang YP, Burke DA: The role of directly applied hypothermia in spinal cord injury. Spine 2000, 25(18): 2294-2302
27. Doppman JL, Girton M, Popovsky MA: Acute occlusion of the posterior spinal vein. Experimental study in monkeys. J Neurosurg 1979, 51: 201-205
28. th Ed, Oxford, New York, Toronto; Oxford University Press, 1980, pp140-142
29. Ducker TB, Kindt GW, Kempe LG, Colonel MC: Pathological findings in acute experimental spinal cord trauma. J Neurosurg 1971, 35: 700-708
30. Duma ST, Mutz N: Efficacy of a peptide-dextran combination (Ceredex) in the treatment of head-brain injuries. Neuropsych 1990, 4: 69-72
31. Fujimoto T, Nakamura T, Ikeda T, et al. Effects of EPC-K1 on lipid peroxidation in experimental spinal cord injury. Spine 2000, 25(1): 24-29
32. George ER, Scholten DJ, Buechler CM, et al: Failure of methylprednisolone to improve the outcome of spinal cord injuries. Am Surg 1995, 61: 659-664
33. Gemdt SJ, Rodriguez JL, Pawlik, et al: Consequences of high-dose steroid therapy for acute spinal cord injury. J Trauma 1997, 42: 279-284
34. nd Ed, London, Boston, Sydney; Butterworths, 1982, pp315-410
35. Geisler FH, Dorsey FC, Coleman WP: Recovery of motor function after spinal cord injury: A randomised, placebo-controlled trial with GM-1 ganglioside. N Engl J Med 1991, 324: 1829-1838
36. Greisler FH, Coleman WP, Grieco G, et al: The GM1 ganglioside multicentre acute spinal cord injury study. Spine 2001, 26(24): 87-98
37. Gschanes A, Windish M: The influence of cerebrolysin and E021 on spatial navigation of 24-month-old rats. J Neural Transm 1998, 53: 313-321
38. Haninec P, Houst'ava L, Stejskal L, Dubovy P: Rescue of rat spinal motoneurons from avulsion-induced cell death by intrathecal administration of IGF-I and cerebrolysin. Ann Anat 2003, 185(3): 233-238
39. Jelsma T, Aguayo A: Trophic factors. Curr Opin Neurobiol 1994, 4: 717-725
40. Joint section on Disorders of the Spine and Peripheral Nerves of the American Association of Neurological Surgeons and the Congress of Neurological Surgeons: Guidelines for the Management of Acute Cervical Spine and Spinal Cord Injuries. Neurosurg 2002, 50: 63-72
41. Koppi S, Barolin GS: Hämodilutionstherapie mit nervenzellstoffwechselaktiver Therapie beim einer Vergleichs-studie. Wien Med Wschr 1996, 146: 41-48
42. Koroleva VI, Koroleva OS, Loseva E, Bures J: The effect of MK-801 and of brain derived polypeptides on the development of focal brain ischaemia induced by photothrombotic occlusion of distal middle cerebral artery in rats. Brain Res 1998, 786(1-2): 104-114
43. Ladurner G: Neuroprotection in acute ischaemic stroke. Stroke 2001, 32(1): 323
44. Legos JJ, Gritman KR, Tuma RF, Young WF: Co-administration of methylprednisolone with hypertonic saline solution improves overall neurological function and survival rates in a chronic model of spinal cord injury. Neurosurg 2001, 49: 1427-1433
45. Lindner G: über die Wirkung von Hirnextrakt und-hydrolysat auf das Nervengewebe unter In-vitro-Bedingungen. Z mikros-anat Forsch 1975, 89: 815-823
46. Mallory M, Honer W, Hsu L, Rockenstein E: In vitro synaptotrophic effect of cerebrolysin in NT2N cells. Acta Neuropathol 1999, 97: 437-446
47. Masliah E, Amorsolo F, Veinbergs I, et al: Cerebrolysin ameliorates performance deficits and neuronal damage in apolipoprotein E-deficient mice. Pharmacol Biochem Beh 1999, 62: 238-245
48. Matsumoto J, Tamaki T, Kawakami M, et al. Early complications of high dose methylprednisolone sodium succinate treatment in the follow up of acute cervical spinal cord injury. Spine 2001, 26: 426-430
49. Means ED, Anderson DK: Neurophagia by leucocytes in experimental spinal cord injury. J Neuropathol Exp Neurol 1983, 42: 707-719
50. Ono T, Takahashi M, Nakamura Y, et al: Report on face run, clinical trial of FPF 1070 (cerebrolysin) injection-one time administration and repetitive administration test. Jap Pharmacol Therapeut 1992, 20: 4-20
51. Paier BH, Steiner E, Windisch M: Cerebrolysin protects isolated cortical neurons from neurodegeneration after brief histotoxic hypoxia. J Neural Transm 1998, 53: 351-361
52. Paier BH, Fruhwirth GM, Windisch M: Further evidence that cerebrolysin protects cortical neurons from neurodegeneration in vitro. J Neural Transm 1998, 53: 363-372
53. Piswanger A, Paier BH, Windisch M. Modulation of protein synthesis in a cell-free system from rat brain by cerebrolysin during the development and aging. Amino Acids 1990, 651-657
54. Pointillart V, Pititjean ME, Wiant L, et al: Pharmacological therapy of spinal cord injury during the acute phase. Spinal Cord 2000, 38: 71-76
55. Rainer M, Brunnbauer M, Dunky A, et al: Therapeutic results with cerebrolysin in the treatment of dementia. Wien Med Wschr 1997, 147: 426-431
56. Reinprecht I, Gschanes, A Windisch M, Fachback G: Two peptidergenic drugs increase the synaptophysin immunoreactivity in brains of 24-month-old rats. Histochem J 1999, 14: 12-32
57. th Congress of the European College of Neuropsychopharm (ECNP). Munich, Germany, 2000, 9: 9-13
58. Rüther E, Ritter R, Apecechea M, et al: Efficacy of the peptidergic nootropic drug cerebrolysin in patients with senile dementia of the Alzheimer type (SDAT). Pharmacopsychiat 1994, 27: 32-40
59. Satou T, Itoh T, Tamai Y, et al: Neurotrophic effects of FPF-1070 (cerebrolysin) on cultured neurons from chicken embryo dorsal root ganglia, ciliary ganglia, and sympathetic trunks. J Neural Transm 2000, 107(11): 1253-1262
60. Schwab ME, Bartholdi D: Degeneration and regeneration of axons of lesion spinal cord. Physiol Rev 1996, 76: 319-370
61. Shimazu S, Iwamoto N, Akasako A, et al: Neurotrophic activity of cerebrolysin. Second International Springfield Symposium on Advances in Alzheimer Therapy, Springfield, USA, 1991, p51
62. Shimazu S, Iwamoto N, Tachikawa N, et al: The neurotrophic action and brain protective effect of cerebrolysin. Neurobiol Aging 1992, 13: 50
63. Sugita Y, Kondo T, Kanazawa A, et al: Protective effect of FPF 1070 (cerebrolysin) on delayed neuronal death in the gerbil-detection of hydroxyl radical with salicylic acid. Brain and Nerve 1993, 45: 325-331
64. Tariov IM, Klinger H: Spinal cord compression studies. Arch Neurol Psychiatr 1954, 71: 271-290
65. Tator CH: Update on the pathophysiology and pathology of acute spinal cord injury. Brain Pathol 1995, 5: 407-413
66. Tator CH, Fehlings MG: Review of the secondary injury theory of acute spinal cord trauma with emphasis on vascular mechanisms. J Neurosurg 1991, 75: 15-26
67. Tator CH, Koyanagi I: Vascular mechanisms in the pathophysiology of human spinal cord injury. J Neurosurg 1997, 86: 483-492
68. Valouskova V, Francis-Turner L: Nerve growth factor and nootropic drug cerebrolysin but not fibroblast growth factor can reduce spatial memory impairment elicited by fimbria-fornix transsection: Short-term study. Neurosci Lett 1996, 202: 193-196
69. th annual meeting of the Society for Neuroscience. New Orleans, USA, 1997
70. Veinbergs I, Mante M, Mallory M, Masliah E: Neurotrophic effects of cerebrolysin in animal models of excitotoxicity. J Neural Transm 2000, 59: 273-280
71. Vereshagin NV, Nekrasova YM, Lebedova NV, et al: Mild forms of multi-infarct dementia: efficacy of cerebrolysin. Sov Med 1991, 11: 1-6
72. Vilenskii BS, Odinak MM, Shirokov EA, et al:P The experience with endolumbar application of cerebrolysin in hemispheric ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova 2000, 100(11): 31-34
73. Vole D, Adler J, Dunky A, et al: Therapeutic effects of cerebrolysin in stroke patients during rehabilitation. Euro Rehab 1998, 3-4: 21-28
74. Wagnar FC, Dohrmann GJ, Bucy P: Histopathology of transitory traumatic paraplegia in the monkey. J Neurosurg 1971, 35: 272-276
75. Wang R, Ehara K, Tamaki N: Spinal cord oedema following freezing injury in the rat: Relationship between tissue and water content and spinal cord blood flow. Surg Neurol 1993, 39: 348-354
76. Windisch M, Albrech E, Eggenreich U, Paier B. Neurotrophic effects of the nootropic drug cerebrolysin - A summary. Neurobiol Aging 1992, 13: 133
77. th International Child Neurology Congress. Ljubljana, Slovenia, 1998